References
United States Food and Drugs Agency approval of teriparatide for use in men and postmenopausal women with osteoporosis in 2003. Available at http://www.fda.gov/cder/foi/appletter/2002/21318.pdf
European Medicines Agency approval of teriparatide for use in men with osteoporosis in 2007. Available at http://www.emea.europa.eu/ humandocs/Humans/EPAR/forsteo/forsteo.htm
Arden NK, Earl S, Fisher DJ et al (2006) Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 17:1626–1629
National Statistics. UK map collection. NUTS/LAUs area maps—NUTS levels 1–3, LAUs level 1. Available at http://www.statistics. gov.uk /geography/maps.asp
National Statistics. Census 2001. National level English regions. Available at http://www.statistics.gov.uk/census2001/pyramids/pages/uk.asp
Acknowledgement
We are thankful to Ms. Victoria Owen and Ms. Sarah Armstrong of the Trent Research and Development Support Unit for statistical analysis and Ms. F. Damato from Healthcare at Home for providing the data.
Funding
None of the authors have received any funding for this study.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abhishek, A., Pande, I. Teriparatide in men: persistence and geographical variation in the UK. Osteoporos Int 20, 1453–1454 (2009). https://doi.org/10.1007/s00198-008-0788-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-008-0788-7